Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study

被引:0
|
作者
Casamitjana, Adria [1 ]
Petrone, Paula [2 ]
Luis Molinuevo, Jose [2 ,3 ,4 ,5 ]
Domingo Gispert, Juan [2 ,3 ,4 ]
Vilaplana, Veronica [1 ]
机构
[1] Univ Politecn Cataluna, UPC BarcelonaTech, ES-08034 Barcelona, Spain
[2] BarcelonaBeta Brain Res Ctr, Barcelona 08005, Spain
[3] Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid 28029, Spain
[4] Univ Pompeu Fabra, Barcelona 08002, Spain
[5] CIBER FES, Madrid 28029, Spain
关键词
Latent model; PLS; preclinical AD; CSF biomarkers; MRI; MILD COGNITIVE IMPAIRMENT; CSF BIOMARKERS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; CORTICAL THICKNESS; NATIONAL INSTITUTE; CEREBRAL-CORTEX; MRI; MCI; AD;
D O I
10.1109/JBHI.2019.2932565
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Magnetic resonance imaging (MRI) provides high resolution brain morphological information and is used as a biomarker in neurodegenerative diseases. Population studies of brain morphology often seek to identify pathological structural changes related to different diagnostic categories (e.g.: controls, mild cognitive impairment or dementia) which normally describe highly heterogeneous groups with a single categorical variable. Instead, multiple biomarkers are used as a proxy for pathology and are more powerful in capturing structural variability. Hence, using the joint modeling of brain morphology and biomarkers, we aim at describing structural changes related to any brain condition by means of few underlying processes. In this regard, we use a multivariate approach based on Projection to Latent Structures in its regression variant (PLSR) to study structural changes related to aging and AD pathology. MRI volumetric and cortical thickness measurements are used for brain morphology and cerebrospinal fluid (CSF) biomarkers (t-tau, p-tau and amyloid-beta) are used as a proxy for AD pathology. By relating both sets of measurements, PLSR finds a low-dimensional latent space describing AD pathological effects on brain structure. The proposed framework allows us to separately model aging effects on brain morphology as a confounder variable orthogonal to the pathological effect. The predictive power of the associated latent spaces (i.e., the capacity of predicting biomarker values) is assessed in a cross-validation framework.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [1] Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease
    Casamitjana, Adria
    Vilaplana, Veronica
    Petrone, Paula
    Luis Molinuevo, Jose
    Domingo Gispert, Juan
    PREDICTIVE INTELLIGENCE IN MEDICINE, 2018, 11121 : 60 - 67
  • [2] Progress Update: Fluid and Imaging Biomarkers in Alzheimer's Disease
    Sutphen, Courtney L.
    Fagan, Anne M.
    Holtzman, David M.
    BIOLOGICAL PSYCHIATRY, 2014, 75 (07) : 520 - 526
  • [3] Structural imaging biomarkers of Alzheimer's disease: predicting disease progression
    Eskildsen, Simon F.
    Coupe, Pierrick
    Fonov, Vladimir S.
    Pruessner, Jens C.
    Collins, D. Louis
    NEUROBIOLOGY OF AGING, 2015, 36 : S23 - S31
  • [4] Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease
    Alexopoulos, Panagiotis
    Kriett, Laura
    Haller, Bernhard
    Klupp, Elisabeth
    Gray, Katherine
    Grimmer, Timo
    Laskaris, Nikolaos
    Foerster, Stefan
    Perneczky, Robert
    Kurz, Alexander
    Drzezga, Alexander
    Fellgiebel, Andreas
    Yakushev, Igor
    ALZHEIMERS & DEMENTIA, 2014, 10 (06) : 684 - 689
  • [5] Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to
    Henriques, Adriane Dallanora
    Benedet, Andrea Lessa
    Camargos, Einstein Francisco
    Rosa-Neto, Pedro
    Nobrega, Otavio Toledo
    EXPERIMENTAL GERONTOLOGY, 2018, 107 : 169 - 177
  • [6] Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimer's Disease Continuum
    Alm, Kylie H.
    Bakker, Arnold
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 70 (04) : 965 - 981
  • [7] Biomarkers for the Early Stages of Clinical Development in Alzheimer's Disease
    Bordet, Regis
    Dartigues, Jean-Francois
    Dubois, Bruno
    Goehrs, Jean-Marie
    Vernoux, Laura
    Semah, Franck
    Pasquier, Florence
    Bidaut-Mazel, Claude
    THERAPIE, 2010, 65 (04): : 285 - 290
  • [8] Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease
    Alcolea, Daniel
    Vilaplana, Eduard
    Pegueroles, Jordi
    Montal, Victor
    Sanchez-Juan, Pascual
    Gonzalez-Suarez, Andrea
    Pozueta, Ana
    Rodriguez-Rodriguez, Eloy
    Bartres-Faz, David
    Vidal-Pineiro, Didac
    Gonzalez-Ortiz, Sofa
    Medrano, Santiago
    Carmona-Iragui, Maria
    Sanchez-Saudinos, MaBelen
    Sala, Isabel
    Anton-Aguirre, Sofia
    Sampedro, Frederic
    Morenas-Rodriguez, Estrella
    Clarimon, Jordi
    Blesa, Rafael
    Lleo, Alberto
    Fortea, Juan
    NEUROBIOLOGY OF AGING, 2015, 36 (06) : 2018 - 2023
  • [9] Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging
    Lim, Ho Jae
    Park, Jung Eun
    Kim, Byeong C.
    Choi, Seong-Min
    Song, Min-Kyung
    Cho, Soo Hyun
    Seo, Hyeon Jeong
    Kim, Jahae
    Song, Ho-Chun
    Choi, Kyu Yeong
    Lee, Jang Jae
    Kim, Hoo-Won
    Ha, Jung-Min
    Song, Woo Keun
    Park, Sung-Gyoo
    Lee, Jung Sup
    Lee, Kun Ho
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 75 (03) : 949 - 958
  • [10] Imaging and biomarkers for Alzheimer's disease
    Allan, Charlotte L.
    Sexton, Claire E.
    Welchew, David
    Ebmeier, Klaus P.
    MATURITAS, 2010, 65 (02) : 138 - 142